After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Thanks to advances in imaging and diagnostic technologies, clinicians can now detect many genetic disorders in the womb, ...

With 300 million people living with rare diseases, experts say new gene and cell therapies are giving families in Wisconsin hope for lasting treatment options.

In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...

USANewsGroup.com News Commentary-- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a ...

Heterotopic ossification (HO) is a common post-surgery condition where bone abnormally forms within soft tissues. A new study out of Mass General Brigham assesses the viability of a simple blood test ...

Iovance Biotherapeutics (NASDAQ:IOVA) gains attention in the Nasdaq Index as biotech sentiment and allocation trends shift.

Sarepta's Doug Ingram and Alkermes' Richard Pops have both announced their retirement and will step down later this year. Two long-serving pharma chief executives have announced their departures, as ...

A new study shows how dysfunctional packaging of the neurotransmitter dopamine triggers toxic processes in neurons—and how ...

For decades, longevity sat at two opposite ends of the spectrum: cutting-edge medicine for the ultra-wealthy, or mass-market ...

Thiruvananthapuram, Feb 28 (UNI) union Minister of State (Independent Charge) for Science and Technology and Minister of State in the Prime Minister’s Office, Jitendra Singh, on Saturday said the ...

After the last meeting when the WGN Radio Book Club discussed their favorite books of 2025, our book lovers – John Williams, Steve Alexander, Bob Kessler, Steve Bertrand and Sara Tieman ...